Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 1 | Clinical Proteomics

Fig. 1

From: Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers

Fig. 1

Separation of various brain tumors by using a combination of plasma GFAP and FABP4. Our preliminary findings [22] have been replicated using MSD immunoassay, instead of Olink PEA technology. (A): 100% specificity threshold. All patients with GFAP < 226 pg/mL (vertical dotted line) and FABP4 > 7,736 pg/mL (horizontal dotted line) had meningioma (blue dots), with 53% sensitivity to detect glioma. (B): Logistic regression model with 64% specificity and 84% sensitivity for meningiomas and gliomas, respectively (shown is the separating dotted line). Cases for whom the diagnosis has changed under the new WHO classification are highlighted with circles, indicating a GBM with wild-type IDH, previously categorized as astrocytoma. Squares indicate astrocytomas with IDH mutation, previously [22] classified as GBM. For more discussion see text

Back to article page

Clinical Proteomics

ISSN: 1559-0275